Document is current
Any future updates will be listed below
-
Authors
Horton, Mary K.
Nititham, Joanne
Taylor, Kimberly E.
Katz, Patricia
Ye, Chun Jimmie
Yazdany, Jinoos
Dall’Era, Maria
Hurabielle, Charlotte
Barcellos, Lisa F.
Criswell, Lindsey A.
Lanata, Cristina M.
-
Funding
Funding for this research was provided by:
National Human Genome Research Institute
Centers for Disease Control and Prevention (U01DP006701, U01DP006701, U01DP006701, U01DP006701, U01DP006701, U01DP006701, U01DP006701, U01DP006701, U01DP006701)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30 AR070155, P30 AR070155, P30 AR070155, P30 AR070155, P30 AR070155, P30 AR070155, P30 AR070155, P30 AR070155)
National Human Genome Research Institute
- License Information
-
More Information
Article History
Received: 15 May 2024
Accepted: 22 November 2024
First Online: 18 December 2024
Declarations
:
: This study was approved by the Institutional Review Board of the University of California, San Francisco (IRB #14–14429). All participants signed a written informed consent to participate.
: NA.
: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.K.H., J.N., K.E.T., P.K., M.D., C.H., L.F.B., L.A.C., and C.L. declare no conflict of interest. C.J.Y. has received consulting fees from Maze Therapeutics, HiBio, Santa Ana, TRex Bio, ImYoo, and DeciBio; received payment for honoraria at Renji Hospital School of Medicine, American College of Medic al Genetics and Genomics, St Jude’s Children’s Research Hospital, Yonsei University College of Medicine, and the Lupus Research Alliance; received support for attending meetings from Icahn School of Medicine at Mount Sinai, Parker Institute for Cancer Immunotherapy, Renji Hospital School of Medicine, Northwestern University Feinberg School of Medicine, and St Jude’s Children’s Research Hospital; participated on advisory/data safety monitoring board for DropPrint Genomics and Related Sciences; leadership role in other boards/societies/groups including Survey Genomics, Arc Institute, and DropPrint Genomics; has stock in Survey Genomics, Related Sciences, Maze Therapeutics, and DropPrint Genomics; has received equipment or gifts/service from Illumina; and has other financial or non-financial interests at Chan Zuckerberg Initiative, Genentech, ScaleBio, Parker Institute for Cancer Immunotherapy, Chan Zuckerberg Biohub, BioLegend, and Illumina. J.Y. has grant/contracts from Gilead, Astra Zeneca, and BMS Foundation; has received consulting fees from Astra Zeneca, Aurinia, Pfizer, Immpact Bio, and Adelphi Values; and is the research lead for the ACR RISE registry.
